Eur J Heart Fail: Relationship between roomic tatroidal hyperthroidation, laboratory early arrest, and mortality in patients with lung, colon, or pancreatic cancer

Many cancer patients die of cardiovascular disease and sudden death, but data on the prevalence and prognostic significance of cystic arrhythmics are not yet clear.
, researchers recruited 120 unfiltered patients with unfiltered lung, colon or pancreatic cancer between 2005 and 2010 in a study published in the leading journal of cardiovascular science, European Journal of Heart Failure, with one of three diagnoses: colorectal cancer (n=33), pancreatic cancer (n=54) or non-small cell lung cancer (n=33), all of which were not significant cardiovascular diseases.
researchers compared them with 43 healthy controls with similar age and gender distributions.
24-hour electrostatimal recording of each participant and followed cancer patients for up to 12.5 years (median 21 months).
96 (80%) cancer patients died during follow-up (five-year lifetime: 27% (95% CI 19-35%).
, non-persistent roomary tatia (NSVT) was more frequent in cancer patients (8% vs. 0%, p.021) than in the control group.
, the number of laboratory-based early fights (PVC) in cancer patients did not increase within 24 hours compared to the control group (median was 4 vs. 9, p s 0.2).
In multivariate analysis, NSVT (HR is 2.44, p s 0.047) and PVCs (1.021 per 100 HR, p s0.047) are important predictors of mortality, independent of other single-variable mortality prediction indicators, including tumor stages, cancer types, potassium concentrations, past surgery, heart toxicity chemotherapy, and hemoglobin.
PVCs≥50/24-hour predictable mortality rate (HR 2.30, p-0.0024) was found in 18% and 26% of patients, respectively, in colorectal and pancreatic cancer patients.
this, it can be seen that colorectal cancer, pancreatic cancer and non-small cell lung cancer patients, non-persistent roomular tatroidal tatia is more common, and together with PVC can predict long-term mortality.
increases the likelihood that cardiovascular mortality will be targeted for future treatment interventions for certain cancers.
。